Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparison of Continuous Moderate Training and Reduced High Intensity Interval Training in Obese Young Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04209647
Recruitment Status : Completed
First Posted : December 24, 2019
Last Update Posted : December 26, 2019
Sponsor:
Information provided by (Responsible Party):
Yasemin Çırak, İstinye University

Brief Summary:
Exercise is a key component of obesity management. Obese subjects cannot attend or sustain exercise program because of increased general fatigue, dyspnea and muscle fatigue. And they feel more exertion when comparing with normal weight subjects. Reduced-exertion high-intensity interval training (REHIT) is a alternative method to continuous exercise programs. The investigators aimed comparing metabolic effects of REHIT and continuous exercise in young adults, in this study.

Condition or disease Intervention/treatment Phase
Obesity Exercise Oxygen Consumption Other: REHIT Exercise Other: Continuous Aerobic Exercise Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparison of Reduced HIIT and Moderate Intensity Continuous Exercise in Obese Young Adults
Actual Study Start Date : May 1, 2018
Actual Primary Completion Date : April 1, 2019
Actual Study Completion Date : August 1, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Continuous Exercise
At %60 of maximal heart rate, 30-60 minutes exercise
Other: Continuous Aerobic Exercise
At %50 of maximum heart rate, 30-60 minutes aerobic exercise

Experimental: REHIT Exercise
At %100 of heart rate 15 seconds, after this period 15 sec recovery period for all step
Other: REHIT Exercise

-Start with warm-up period --> %50 of maximum work rate, 3 minutes

One Exercise Cycle consists of:

  • 15 seconds exercise period: %100 of maximum work rate
  • 15 seconds recovery period: %50 of maximum work rate

Total Duration: 10 minutes





Primary Outcome Measures :
  1. Aerobic Capacity [ Time Frame: 1 year ]
    Maximum Oxygen Uptake


Secondary Outcome Measures :
  1. Total Exercise Duration [ Time Frame: 1 year ]
    Exercise Test Duration


Other Outcome Measures:
  1. Body Fat Percentage [ Time Frame: 1 year ]
    Total Body Fat Percentage



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 22 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Between the ages of 18-22,
  • BMI ≥ 30,
  • Female gender,

Exclusion Criteria:

  • Smoking history,
  • Having any metabolic disease except obesity,

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04209647


Locations
Layout table for location information
Turkey
Istınye University
Istanbul, Turkey
Sponsors and Collaborators
İstinye University
Investigators
Layout table for investigator information
Study Chair: Nurgul Durustkan Elbasi, PhD Istinye University
Study Chair: Yunus Emre Tutuneken, PT Istinye University
Principal Investigator: Yasemin Cirak, Ass Prof Istınye U
Study Chair: Duygu Korkem, PhD University of Health Science
Study Chair: Beyza Karaduz, MsC Hacettepe University
Study Chair: Ebru Calik Kutukcu, PhD Hacettepe University
Layout table for additonal information
Responsible Party: Yasemin Çırak, Associate Proffesor, İstinye University
ClinicalTrials.gov Identifier: NCT04209647    
Other Study ID Numbers: 0004
First Posted: December 24, 2019    Key Record Dates
Last Update Posted: December 26, 2019
Last Verified: December 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No